proposes to study the (9) . In terms of nonclinical toxicology studies, this means that a sponsor should conduct reproductive toxicity studies in animals to determine the effects of the drug on fertility, reproductive performance, teratology, and prenatal/postnatal development. Over the years the FDA has developed a well-characterized system of reproductive toxicology/teratology studies (6, 7) . Although it is beyond the scope of this paper to describe in detail these assays, it should be emphasized that these studies should be conducted as soon as possible. Clinical studies in women of childbearing potential are encour-aged (5 
